136 related articles for article (PubMed ID: 2513813)
1. Stimulation of vascular prostacyclin and inhibition of platelet function by oral defibrotide in cholesterol-fed rabbits.
Löbel P; Schrör K
Atherosclerosis; 1989 Nov; 80(1):69-79. PubMed ID: 2513813
[TBL] [Abstract][Full Text] [Related]
2. Changes in platelet reactivity, prostacyclin and thromboxane production after long-term oral defibrotide in healthy and atherosclerotic rabbits.
Löbel P; Palmér M; Schrör K
Prog Clin Biol Res; 1987; 242():265-70. PubMed ID: 3313414
[No Abstract] [Full Text] [Related]
3. Selective stimulation of coronary vascular PGI2 but not of platelet thromboxane formation by defibrotide in the platelet perfused heart.
Löbel P; Schrör K
Naunyn Schmiedebergs Arch Pharmacol; 1985 Nov; 331(2-3):125-30. PubMed ID: 3937058
[TBL] [Abstract][Full Text] [Related]
4. Effects of defibrotide on aorta and brain malondialdehyde and antioxidants in cholesterol-induced atherosclerotic rabbits.
Aydemir EO; Duman C; Celik HA; Turgan N; Uysal A; Mutaf I; Habif S; Ozmen D; Nişli N; Bayindir O
Int J Clin Lab Res; 2000; 30(2):101-7. PubMed ID: 11043504
[TBL] [Abstract][Full Text] [Related]
5. Stimulation of prostacyclin synthesis by defibrotide: improved contractile recovery from myocardial "stunning".
Hohlfeld T; Strobach H; Schrör K
J Cardiovasc Pharmacol; 1991 Jan; 17(1):108-15. PubMed ID: 1708043
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effects of a thromboxane receptor antagonist (BM 13.505) on platelet hyperreactivity and thromboxane formation in cholesterol-fed rabbits.
Löbel P; Schrör E; Schrör K
Biomed Biochim Acta; 1988; 47(10-11):S86-9. PubMed ID: 3073772
[TBL] [Abstract][Full Text] [Related]
7. Fibrinolytic effects of defibrotide in atherosclerotic patients.
Patrassi GM; Sartori MT; Viero ML; Scapinello MP; Boeri G; Girolami A
Semin Thromb Hemost; 1991; 17 Suppl 1():101-5. PubMed ID: 2068562
[TBL] [Abstract][Full Text] [Related]
8. Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacyclin in type IIa hypercholesterolemia.
Schrör K; Löbel P; Steinhagen-Thiessen E
Eicosanoids; 1989; 2(1):39-45. PubMed ID: 2483819
[TBL] [Abstract][Full Text] [Related]
9. Defibrotide's activity on leukocytes and platelets in rabbits with diet-induced atherosclerosis.
Pescador R; Tettamanti R; Salvetti L; Conto A; Porta R; Mantovani M; Ferro L
Agents Actions Suppl; 1995; 45():323-7. PubMed ID: 7717197
[TBL] [Abstract][Full Text] [Related]
10. Effects of defibrotide on prostacyclin release from isolated rabbit kidneys and protection from post-ischemic acute renal failure in vivo.
Berti F; Rossoni G; Bianchi G; Alberico P; Tettamanti R; Calvani AB; Mantovani M; Prino G
Eicosanoids; 1991; 4(4):209-15. PubMed ID: 1789997
[TBL] [Abstract][Full Text] [Related]
11. Endothelial protection by defibrotide--a new strategy for treatment of myocardial infarction?
Schrör K; Ackermann G; Hohlfeld T; Löbel P; Ney P; Schröder H; Strobach H
Z Kardiol; 1989; 78 Suppl 6():35-41. PubMed ID: 2559554
[TBL] [Abstract][Full Text] [Related]
12. Oral naftidrofuryl prevents platelet hyperreactivity ex vivo and inhibits functional desensitization to prostacyclin in hypercholesterolemic rabbits.
Weber AA; Hohlfeld T; Strobach H; Schrör K
J Cardiovasc Pharmacol; 1993 Feb; 21(2):332-8. PubMed ID: 7679170
[TBL] [Abstract][Full Text] [Related]
13. Stimulation of endogenous prostacyclin protects the reperfused pig myocardium from ischemic injury.
Hohlfeld T; Strobach H; Schrör K
J Pharmacol Exp Ther; 1993 Jan; 264(1):397-405. PubMed ID: 8423539
[TBL] [Abstract][Full Text] [Related]
14. Novel mechanism of action of a prostacyclin enhancing agent in haemorrhagic shock.
Bitterman H; Lefer DJ; Lefer AM
Naunyn Schmiedebergs Arch Pharmacol; 1988 Jun; 337(6):679-86. PubMed ID: 3063971
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology and mode of action of a new antithrombotic compound: Defibrotide.
Ulutin ON; Cizmeci G; Balkuv-Ulutin S
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):177-80. PubMed ID: 2459016
[TBL] [Abstract][Full Text] [Related]
16. Defibrotide normalizes cardiovascular function hampered by established atherosclerosis in the rabbit.
Rossoni G; Berti F; Trento F; Cattaneo F; Porta R; Pescador R; Ferro L
Thromb Res; 2000 Jan; 97(2):29-38. PubMed ID: 10688332
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of defibrotide in protecting ischemic myocardium from early reperfusion damage.
Thiemermann C; Löbel P; Schrör K
Am J Cardiol; 1985 Dec; 56(15):978-82. PubMed ID: 3907318
[TBL] [Abstract][Full Text] [Related]
18. Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man.
Coccheri S; Biagi G; Legnani C; Bianchini B; Grauso F
Eur J Clin Pharmacol; 1988; 35(2):151-6. PubMed ID: 3191933
[TBL] [Abstract][Full Text] [Related]
19. Chronic oral defibrotide counteracts hypercholesterolemia noxious effects on cardiovascular function in the rabbit.
Rossoni G; Berti F; Trento F; Cattaneo F; Porta R; Pescador R; Ferro L
Thromb Res; 1999 Jun; 94(5):327-38. PubMed ID: 10379821
[TBL] [Abstract][Full Text] [Related]
20. Favourable effect of defibrotide in lipid A-induced shock in pigs.
Hohlfeld T; Bucha E; Nowak G; Brüggener E; Strobach H; Schrör K
Circ Shock; 1992 Oct; 38(2):122-9. PubMed ID: 1423920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
